Natera, Inc. (NTRA) Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on August 6, 2026.
Q2 2026
EPS
-$0.47
est -$0.53
+12.0%
Revenue
$753M
est $661M
+13.8%
Management lifted full-year revenue guidance $100 million at the midpoint to $2.85 billion to $2.91 billion after oncology test volumes jumped 57.2% year over year. Signatera's FDA companion diagnostic approval in bladder cancer, plus Japanese and EU clearances, widens the market behind that raise. FIND-CRC enrollment wraps in Q3.
Mentioned: NTRA